Irsogladine maleate (JP17); Gaslon N (TN). Formula. C9H7Cl2N5. C4H4O4. Exact mass. Mol weight. Structure, Mol file KCF file DB search. View and buy high purity Irsogladine maleate from Tocris Bioscience. PDE4 inhibitor; antiulcer agent. Description. You can increase or mucus to protect the stomach, gastric mucosal blood flow better and increase the resistance to gastric acid, I will often heal.
|Published (Last):||24 February 2015|
|PDF File Size:||6.91 Mb|
|ePub File Size:||5.36 Mb|
|Price:||Free* [*Free Regsitration Required]|
This ion product was assigned to the 5-dimethylaminonaphthalenesulfonyl moiety derived from the positively ionized DH derivatives. Of note, no clear histopathological changes were observed by irsogladine maleate treatment to the stomach Figure S2. The maximal number of polyps was observed in the size range up to 3.
In the colon, no remarkable change was observed following treatment with irsogladine maleate. We chose six gastric mucosal protectants ecabet sodium hydrate, irsogladine maleate, rebamipide, sofalcone, teprenone and troxipide and examined their effects on the activity of oxidative irsogladjne transcriptional factors, including AP-1, NF-jB, NRF2, p53 and STAT3, in Caco-2 cells using a luciferase reporter gene assay.
KEGG DRUG: Irsogladine maleate
Prevents gastric mucosal injury induced by monochloramine and ischemia-reperfusion. Citations for Irsogladine maleate Citations are publications that use Tocris products.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and irsolgadine are credited. Volume to add to vial ml ul.
Lipidomic analysis for lipid peroxidation-derived aldehydes using gas chromatography-mass spectrometry. Cell culture Caco-2 cells, a human colon adenocarcinoma cell line, were purchased from Sumitomo Dainippon Pharma Co. At the sacrifice time points, mice were anesthetized, and blood samples were collected from the abdominal vein. In the maelate study, irsogladine maleate was selected from a group of six gastric mucosal protectants following through screening methods to evaluate their suppressive activities on multiple oxidative stress-related transcription factors.
Sign-up for new product e-alerts. Your account has been deactivated. Mass in vial mg ug ng. Inhibition of PDE4 prevents the hydrolysis of cAMP, an important secondary messenger molecule that is heavily involved in signal transduction. We benefitted from the technical support of Mrs.
The numbers and sizes of polyps and their distributions in the intestine were assessed with a stereoscopic microscope. However, this potential has not been clarified, and screening methods that completely evaluate the activities of oxidative stress-related transcriptional factors have not been performed. Furthermore, the chemopreventive property of irsogladine maleate was examined in a Min mouse model of familial adenomatous polyposis.
Aspirin for the chemoprevention of colorectal adenomas: Click on image or enlarge button to enlarge. The technical data provided above is for guidance only. Nozaki et al Inhibition of breast cancer regrowth and pulmonary metastasis in nude mice by anti-gastric ulcer agent, irsogladine. Received Aug 31; Accepted Jan Activation of interleukin-6 gene expression through the NF-kappa B transcription factor.
Therefore, the suppression of oxidative stress in Min mice by irsogladine maleate could be related to the reduction of intestinal tumorigenesis. This study demonstrated that irsogladine maleate suppresses intestinal polyp formation in Min mice partly through the NF-jB signaling pathway, thus reducing oxidative stress. All of the free RCs detected in the liver samples taken from 0 A.
Abstract This study aimed to identify gastric mucosal protectants that suppress intestinal tumorigenesis in a mouse model. This study aimed to identify gastric mucosal protectants that suppress intestinal tumorigenesis in a mouse model. Irskgladine linear gradient conditions were as follows: Reviews for Irsogladine maleate There are currently no reviews for this product. Akakabe Y, Nyuugaku T. Creating an account with us makes your shopping experience much easier and faster.
Identification of a pathogen-inducible oxygenase piox as an alpha-dioxygenase and biosynthesis of 2-hydroperoxylinolenic acid. In addition, there were no observed changes in organ weights that might have been attributable to toxicity. Thus, we aimed to identify an ideal gastric mucosal protectant with anti-oxidative stress and anti-intestinal tumorigenesis irsolgadine.
Sign Up for Santa Cruz Biotechnology news and announcements. As far as we know, this is the first report to examine the effects of irsogladine maleate on intestinal neoplastic lesions. Mobile phase A consisted irsogladdine a 0. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
Email address is required. There are currently no reviews for this product. In fact, to our knowledge, no descriptions of severe side effects of irsogladine maleate treatment have been reported in the literature. The data suggested the effects of 5 ppm irsogladine maleate plateaus, and higher doses did not efficiently decrease polyp numbers.
Please provide a valid email address. The areas of the circles represent the intensities of the peaks of the detected RCs relative to that of the IS.
Preparing Stock Solutions The following data is based on the product molecular weight Among the six irsogladinw, irsogladine maleate clearly inhibited NF-jB and AP-1 transcriptional activity.
For example, lipid peroxidation-induced exocyclic DNA adduct levels are significantly increased in the affected organs of cancer-prone subjects suffering from Crohn’s disease, chronic hepatitis, chronic pancreatitis and familial adenomatous polyposis [ 24 ].
Chemical structures of six gastric mucosal protectants Irsogladine maleate A. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.